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Abstract
Background: Pemetrexed, a multi-folate inhibitor combined with a platinum compound is the first-line treatment of
malignant mesothelioma, but median survival is still one year. Intrinsic and acquired resistance to pemetrexed is common,
but its biological basis is obscure. Here we report for the first time a genome-wide profile of acquired resistance in the
tumour from an exceptional case with advanced pleural mesothelioma and almost six years survival after 39 cycles of
second-line pemetrexed/carboplatin treatment.
Methodology and Principal Findings: Genome-wide analysis with Illumina BeadChip Kit of 25,000 genes was performed on
mRNA from pre-treatment and post-resistance biopsies from this individual as well on case and control samples from our
previously published study (in total 17 samples). Cell specific expression of proteins encoded by selected genes were
analysed by immunohistochemistry. Serial serum levels of CA125, CYFRA21-1 and SMRP levels were examined. TS protein,
the main target of pemetrexed was overexpressed. Proteins and genes related to DNA damage response, elongation and
telomere extension and repair related directly and indirectly to platinum resistance were overexpressed, as the CHK1
protein and the genes CHEK2, LIG3, POLD1, POLA2, FANCD2, PRPF19, RECQ5 respectively, the last two not previously
described in mesothelioma. We observed a down-regulation of leukocyte transendothelial migration and cell adhesion
molecules pathways. Silencing of NT5C in two mesothelioma cell lines did not sensitize the cells to Pemetrexed. Proposed
resistance markers are TS, KRT7/ CK7, TYMP/ thymidine phosphorylase and down-regulated SPARCL1 and CDKN1B.
Moreover, comparison of the primary expression of the sensitive versus a primary resistant case showed multi-fold
overexpressed DNA repair, cell cycle, cytokinesis, and spindle formation in the latter. Serum CA125 and SMRP reflected the
clinical and radiological course and tumour burden.
Conclusions: Genome-wide microarray of mesothelioma pre- and post-resistance biopsies indicated a novel resistance
signature to pemetrexed/carboplatin that deserve validation in a larger cohort.
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Introduction
Malignant mesothelioma, an aggressive tumour of the pleura
and peritoneum, represents a clinical challenge as the incidence
increases worldwide, and will continue to increase due to extensive
asbestos use in several developing countries [1]. The most effective
treatment proven to prolong life of malignant mesothelioma
patients is the combination of multi-folate inhibitors, pemetrexed
or raltitrexed and cisplatin, but still the median survival is only 12
months, and response rates are approximately 40% [2]. Thus,
almost half of the patients are primary resistant and all finally
develop resistance. Thymidylate synthase is considered the main
target of pemetrexed and current studies indicate that low
expression levels of this protein is predictive for good pemetrexed
response, longer time to progression and overall survival [3,4,5,6],
but the mechanisms and pathways involved in pemetrexed
resistance are inadequately elucidated. Several mechanisms of
platinum resistance have been described, involving among others
the DNA repair system [7], but for mesothelioma treatment still no
useful marker has emerged. A resistance profile or signature could
have important clinical implications. We recently reported that the
gene profile of pleural mesothelioma correlates to several known
chemo- and radiation-resistance mechanisms, reflecting the
generally resistant mesothelioma phenotype [8]. One of the
patients included in our genome-wide expression study responded
on pemetrexed and carboplatin for 39 cycles as second-line
treatment. At treatment resistance, after 5 years, a new biopsy was
obtained from the tumour. Genome-wide profiling was performed
as well as immunohistochemistry and serum biomarker expression
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and the pre- and post-resistance profile was assessed in light of the
clinical history. Here we present novel findings and discuss their
relevance for mesothelioma treatment resistance and progression.
Methods
Ethics statement
The Regional Committee of Research Ethics of Central
Norway approved the study protocol and oral and written
informed consent was obtained.
Patient history
A 42-year old woman was referred to our clinic in May 2003
with dyspnoea for the last 8 months, and CT scan showed a large
tumour in mediastinum and the left pleura, growing into her left
breast (Fig. 1). She had worked nine years as a hairdresser with no
obvious asbestos exposure, but the department of occupational
medicine discovered that the hair-dryer she had used daily,
contained asbestos coils inside. Diagnostic biopsy and fresh frozen
material was obtained from pleural tumour by transdermal
ultrasound guided biopsy. The histological and immunohisto-
chemical picture showed a clear-cut malignant mesothelioma of
the epithelial type (Table 1). Due to her young age, female gender
and low-grade asbestos exposure, additional tumour markers were
analyzed to exclude other primary solide organ tumours (S-100,
Chromogranin, Thyreoglobulin, Calcitonin, TTF-1, Synaptophy-
sin, CK20), but those were all negative. Stage according to the
IMIG classification was T4N3M0. As first line therapy, six cycles
of carboplatin, pegylated doxorubicin and gemcitabine were given
with partial response, but only with slight improvement of clinical
status. This was before pemetrexed and platinum was standard
treatment. Due to progression almost a year after diagnosis,
second line therapy consisting of pemetrexed (500 mg/m2) and
carboplatin (AUC5) was given every three weeks, with B12 and
folate supplement (Fig. 1). Clinical and radiological response was
seen after six months, and the condition was considered stable for
24 courses (Fig. 1). After a five months treatment pause,
progression was seen and another15 courses of pemetrexed/
carboplatin were given, followed by regression, finally stopped due
to renewed progression (Fig. 1). In total, she received 39 cycles
with minimal toxicity and a self-reported good quality of life.
Clinical manifestation of the last progression was dyspnoea and
CT scan showed increasing tumour volume and pleural fluid
(Fig. 1, June 2008). At that point CT-guided biopsies were
obtained for microarray analysis and immunohistochemistry
(IHC). Peroral Vinorelbine 80mg/m2 at day 1 and 8 was then
tried as a third-line treatment with four months of stable disease.
The last two months she deteriorated and died at the district
hospital. No CT-evaluation or serum samples from that last period
were available.
Biopsies and Microarray analysis
Needle biopsies obtained by CT-guidance were snap frozen for
microarray analysis and formalin-fixed for IHC. A high tumour
content (.50%) in the samples was morphologically verified by
a pathologist (HS). RNA extraction and quality control was done
as described previously [9]. In order to maximize reliability of the
comparative analysis, we performed microarray analysis of four
post-resistance samples (two separate biopsies and two technical
duplicates) as well as the mRNA from all mesothelioma and
parietal pleural samples described in [9] (in total n = 17).
Preparations of 75 ng deep frozen total RNA through first strand
cDNA synthesis, second strand synthesis and IVT-reaction to
make biotin labeled cRNA was performed using IlluminaH
TotalPrep(tm)-96 RNA Amplification Kit (Cat#4393543) (Ap-
plied Biosystems/Ambion, Austin, TX). cRNA was quantified
with a NanoDrop Spectrophotometer (NanoDrop Technologies,
Wilmington, DE) and normalized before hybridized to the
HumanHT-12 v3 Expression BeadChip Kit (Cat# BD-103-
0603) (Illumina, Inc., San Diego, CA) of 25,000 genes. All
applications were performed according to the manufacturer’s
instructions.
After scanning the beads chips the hybridization, biotin
labelling, low stringency, housekeeping and negative controls
was assessed to determine the quality of technical performance of
the bead chips. All control performed as expected (Ref# ‘‘Whole -
Genome Gene Expression with IntelliHyb Seal – System Manual’’
– Illumina, 2006). All experiments are registered in ArrayExpress
according to the MIAME.
Microarray statistical analysis
Three separarate analyses were performed; first the tumour
versus normal analysis on the Illumina and Affymetrix datasets
combined, second on the Illumina dataset aiming at detecting the
post-resistance profile, called the acquired resistance analysis, and
finally a comparison of the most sensitive versus the most resistant
case, using the Affymetrix platform called the intrinsic resistance
analysis.
For the tumour versus normal analysis, our previously published
dataset on mesothelioma versus normal parietal pleura (n = 16) [8]
data with Affymetrix Human Genome U133 Plus 2.0 GeneChip
(Accession number EMTAB-47, www.ebi.ac.uk/arrayexpress/
experiments/E-MTAB-47) and the dataset with the current
Illumina data on the identical samples (Accession number E-
MTAB-1109, www.ebi.ac.uk/arrayexpress/experiments/E-
MTAB-1109) were the Affymetrix raw probe set intensities were
normalised by robust multi array average (RMA) and the Illumina
intensities were log2 and quantile transformed. The control of false
positives was done according to Benjamini and Hochberg [10,11]
and genes with corrected P-values smaller than 0.05 were taken as
significant. The two datasets were separately analysed with the
limma package in Bioconductor (www.bioconductor.org). Robust
rankings were produced by aggregating results of jackknifed
Limma models using the GeneSelector package (www.
bioconductor.org). A list of the 1500 top ranked genes from both
platforms was chosen (this is an ordered list where a p-value is not
available). Moreover, a ranked list of GO terms based on the top
1500 gene-list was produced using Fischers exact test (TopGO
software, www.bioconductor.org).
For the aquired resistance analysis, normalization was done as
previously described. The data from the primary biopsy was
correlated to the averaged data from the biopsies at the time of
treatment failure versus the data of the normal parietal pleura
samples as described in [8]. The annotation from illuminaHu-
manv3. db_1.10.0, hgu133plus2. db_2.5.0, org. Hs.eg.db_2.5.0
(www.bioconductor.org) were used. The lists of significant genes
were tested for overrepresentation in KEGG PATHWAYS (Kyoto
Encyclopedia of Genes and Genomes) [12], and GO (gene
ontology) terms [13] using Fishers exact test (significant p,0.05).
For the intrinsic resistance, the pre-resistance gene expressions
was compared with the gene expression list of another case in our
previously published material with very aggressive disease and
innate resistance to radiotherapy and doxorubicin, gemcitabine
and carboplatin with only six months survival, using the
Affymetrix data [9].
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Immunohistochemistry
Cell specific protein expression encoded by ten mesothelioma-
related genes as well as four standard diagnostic antibodies
(respective gene symbols in brackets) was assessed by IHC.
Calretinin, EMA, CEA and Ber-Ep4 as described in [14] as well as
the following, experimental antibodies were tested on formalin
fixed paraffin embedded tissues adjacent to samples subjected to
microarray: thymidylate synthase (TYMS) (Millipore, Billerica,
MA, USA), dilution 1:50; VG5Q (AGGF1) (Abcam, Cambridge,
UK), dilution 1:500; Chk1 (CHEK1) (Epitomics, CA, USA),
dilution 1:10, overnight incubation at 24uC; NQO1 (NQO1)
(Zymed Laboratories, Carlsbad, CA, USA), dilution 1:50; RAD21
(RAD21) (Abcam, Cambridge, UK), dilution 1:500; mesothelin
(MSLN) (Novocastra Laboratories, Newcastle, UK), dilution 1:10,
overnight incubation at 24uC; thymidine phosphorylase (TYMP/
ECGF1) (Sigma-Aldrich, St. Louis, MO, USA), dilution 1:50;
cytokeratin 7 (CK7) (DAKO, Glostrup, DK), dilution 1:500;
syndecan-1 (CD138) (DAKO, Glostrup, DK), dilution 1:50; hevin
(SPARCL1) (R&D Systems, Abingdon, UK), dilution 1:50.
Selected positive and negative controls were included for all
antibodies. Slides were reviewed by HS and immunoreactivity was
registered as the percentage of stained tumour cells and staining
intensity was scored from 1–4 (Table 1).
Serum biomarker analysis
Blood samples for biomarker analysis were obtained at several
consecutive visits in our hospital, and they were immediately
centrifuged and stored in 220uC for 1–2 days and subsequently in
280uC. Serum samples were analysed ‘‘in batch’’ for CA125,
CYFRA 21–1 and SMRP as described in [15].
NT5C silencing
Silencing of NT5C was performed with two MM cell lines, the
sarcomatoid ZL-34 (kindly provided by Julius Klominek) [16] and
the epithelioid M-14-K (kindly provided by K. Linnainmaa) [17].
In our recent experiments the M-14-K cells were sensitive and the
ZL-34 cells were resistant to Pemetrexed treatment (unpublished
data), making them a suitable pair of cell lines for this study. The
cells were cultivated in 90% Gibco RPMI 1640 medium
(Invitrogen, Carlsbad, CA, USA) with 25 mM HEPES buffer
Figure 1. Thoracic computer tomography (CT) throughout the disease course. A large mediastinal tumour as well as thoracic wall
infiltration was seen on the left side (CT at the same level). For details see Methods.
doi:10.1371/journal.pone.0040521.g001
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and 1% L-glutamine (Invitrogen), together with 10% Bovine
Serum (Invitrogen). All cells were cultured under 37uC and 5%
CO2 conditions and grown to confluency in 75 cm
2 flasks
(Sarstedt, Nu¨mbrecht, Germany). Flasks with confluent cells were
then trypsinized, spun down and approximately 250 000 cells were
seeded in every well of a 6 well plate over night (Nunc, Rochester,
New York, USA). The NT5C expression was then silenced
according to manufacturer’s protocol. Briefly, LipofectamineTM
2000 (Invitrogen) was mixed in medium with siRNA specific for
NT5C (Sigma-Aldrich) (Table S1) or negative control siRNA
(MISSIONH siRNA Universal Negative Control, Sigma-Aldrich)
in siRNA concentration of 40 nM and incubated for 20 min. The
seeded cells were then treated with one of the siRNA-
lipofectamine complexes for 4–6 hours. Following this, fresh
medium and serum was added to the cells and they were grown
for additional 18–20 hours before treatment or harvesting the cells
for RNA isolation.
RNA isolation and Quantitative Real Time Polymerase
Chain Reaction (qRT-PCR)
The silencing of NT5C was validated by qRT-PCR. Cells were
trypsinized, washed in cold PBS and spun down. The RNA was
then extracted using the High Pure RNA Isolation Kit (Roche,
Mannheim, Germany), according to the manufacturer’s protocol.
The purity and the yield of the RNA isolations were measured
using the NanoDrop Spectrophotometer (Nanodrop Technologies
Inc). cDNA were constructed from RNA templates according to
the manufacturer’s protocol using the First-Strand cDNA Synthe-
sis Kit (GE Healthcare, Little Chalfont, Buckinghamshire,
England). In brief RNA was mixed with RNaseOUTTM
Recombinant Ribonuclease Inhibitor (Invitrogen), heated and
then put on ice. Bulk First-Strand cDNA Reaction Mix, DTT
Solution, pd(N)6 Primer and the RNA was then mixed and
incubate for 1 hour. The purity and concentrations of the cDNA
were then measured using the NanoDrop Spectrophotometer.
qRT-PCR was performed using the PlatinumH SYBRH Green
qPCR SuperMix-UDG kit (Invitrogen) according to manufac-
turer’s protocol. The cDNA samples were used in quintuplicate
and sense/antisense primers for either NT5C (Cybergene AB,
Stockholm, Sweden) or GAPDH [18]. We designed the primers
for NT5C using gene sequences from GeneBank (NCBI)
(Table S1). The experiments were run in an iCycler machine
(Bio-Rad, Hercules, CA, USA), analyzed in Bio-Rad CFX
managerTM Software 2.0 and the quantity of NT5C were
normalized to the GAPDH reference gene and presented as mean
values of at least four independent experiments.
Cell cycle analysis
After silencing, the cells were given fresh medium and serum
and treated with either 90 mM Pemetrexed (Lilly, Indianapolis,
IN, USA) or with PBS for the control cells. After 48 hours of
treatment the cells were trypsinized and spun down. Cells were
then fixated by slowly adding cold ethanol while continuously
resuspending the cell pellet. The samples were then stored at 4uC
over night. Following this, cells were washed with PBS and mixed
with staining solution, containing 50 mg/ml Propidium iodide
Table 1. Change of immunohistochemical expression in tumour before and after resistance.
Markers Biopsy 2003 Biopsy 2008
Diagnostic Markers
% positive
MM-cells
Intensity
(0–4)
% positive
MM-cells
Intensity
(0–4)
Gene/Protein
change*
EMA, cytoplasm ,1 1–2 ,1 1 2/2
EMA, cell membrane 40 3 70 3 2/+
Calretinin, nucleus .95 3–4 .95 4 2/2
mCEA 0 0 0 0 2/2
Ber-Ep4 0 0 0 0 2/2
Experimental Markers
RAD21 .90 3–4 .95 4 2/2
CD138, cell membrane 15 3–4 10 3–4 2/2
CHK1, cytoplasm ,5 1–2 50 1–2 2/+
CHK1, nucleus ,1 1–2 1–2 1–3 2/2
CK7, cytoplasm 20 2–4 95 2–4 +/+
CK7, cell membrane
Mesothelin 100 3–4 .99 4 2/2
NQO1, cytoplasm 90 1–3 99 1–3 2/+
NQO1, nucleus 20 1–3 70 1–3
SPARCL, cytoplasm 100 4 100 3–4 --/2
TYMP, cytoplasm 50–60 2–4 85 3–4 +/+
TYMS, cytoplasm ,1 1–2 25 1 +/+
TYMS, nucleus ,1 1–2 ,1 1 +/2
VG5Q, cytoplasm 95 2–3 .99 2–3 2/2
VG5Q, nucleus 1–2 1–3 0 0
*(2) indicates no change, (+) indicate increase and (--) indicate reduction.
Experimental markers are antibodies to proteins encoded by differentially expressed genes in mesothelioma or genes related to mesothelioma biology.
doi:10.1371/journal.pone.0040521.t001
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solution (Sigma-Aldrich) and 100 mg/ml Ribonuclease A (Sigma-
Aldrich) and incubated for 30 min at 37uC. The samples were then
analyzed using FACSCalibur cytometer (Becton Dickinson,
Franklin Lakes, NJ, USA) and CELLQuest pro Software. Cell
cycle distribution was evaluated with the Dean-Jett-Fox model
using FlowJo 7 (Tree Star Inc., Ashland, OR, USA) for Windows.
Statistical Analysis
All the results for the ZL-34 and the M-14-K cells are mean
values of at least four independent experiments. The error bars
represent the 95% confidence intervals and the difference between
the mean values of treated and untreated cells or silenced and
negative control siRNA cells, were analyzed using student’s t-test
with one-tailed p-values. Statistical significance was considered at
p,0.05.
Results
Tumour versus normal analysis
The tumour versus normal analysis as described above showed
an almost identical picture of the Affymetrix and Illumina
platform as seen in the loading and score-plots and differentially
expressed genes were very similar (Figure S1) and there was a 65%
overlap of the differentially expressed genes (Figure S2). The top
1500 ranked list and GO entities of differentially expressed genes
showed an overexpression of genes involved in mitosis, cell cycle
checkpoint and DNA repair and down-regulated multicellular
organismal development, inflammatory response and vasculogen-
esis among others (Table S2 Sheet 1–3).
Acquired resistance analysis
High quality RNA was successfully extracted from the post-
resistance tumour samples and analysed with the Illumina
platform as described. The acquired resistance analysis revealed
241 overexpressed and 289 down-regulated genes in the post-
resistance samples (Table S2 Sheet 4 and 5). There were 23
significantly overexpressed and 65 down-regulated GO-terms
(Table S2 Sheet 6 and 7, p,0.05).
The largest entity of overexpressed genes in numbers was the
metabolic process with 89 genes, whereof 46 genes involved in
nucleobase, nucleoside, nucleotide and nucleic acid metabolic
process. Other overexpressed entities were tRNA aminoacylation,
protein amino acid glycosylation and response to DNA damage
stimulus. Similarly in the KEGG (Kyoto Encyclopedia of Genes
and Genomes [12]), 15 genes were overexpressed in the metabolic
pathways, six and four genes in the pyrimidine (Fig. 2) and purine
metabolism respectively and four genes of the aminoacyl t-RNA
biosynthesis pathway. Several other important pathways as
endocytosis, calcium signalling and ubiquitin mediated proteolysis
were also deregulated (Table 2).
The largest entity of down-regulated genes in number of genes
was the cellular process with 162 genes. Cell communication and
multi-cellular organismal development as well as negative regula-
tion of biological process, transcription and nucleobase, nucleo-
side, nucleotide and nucleic acid metabolic process were down-
regulated. Similarly in KEGG, down-regulation of metabolic
pathways, cell adhesion molecules, leukocyte transendothelial
migration as well as MAPK-signalling pathway and cytokine-
cytokine receptor interaction were the most highly represented
pathways.
Among the differentially expressed acquired resistance genes, 12
overexpressed and 26 down-regulated genes changed more than 2-
fold (Fig. 3).
For examining the relation of acquired resistance genes versus
the general mesothelioma gene signature published in [8], the
1500 top ranked genes were analysed for similarities and we found
150 tumour-specific genes were in common (Table S2 Sheet 8).
Protein expression- IHC
Due to very limited material for immunohistochemistry (needle
biopsy), a careful selection of antibodies was chosen. The
histological picture and routine IHC remained virtually un-
changed before and after resistance, except for cell membrane
EMA staining where immunoreactivity (IR) increased from 40%
to 70% of cancer cells (Table 1). Then, experimental markers
important of aggressiveness as well as resistance in several cancers
as well as mesothelioma, were tested [8]. Damage response protein
CHK1 changed from almost no detectable staining in the primary
biopsy to 50%, nuclear staining of NQO1 increased from 20 to
70% and TYMS staining increased from below 1% to 25% of
tumour cells (Table 1, Fig. 4). RAD21 and mesothelin IHC was
analysed for the same reason but showed no change of gene or
protein staining.
We previously identified VG5Q as a novel angiogenic over-
expressed in mesothelioma [8], but no change was seen. SDC gene
was overexpressed, but its protein Syndecan-1 (CD138) an
important protein related to the mesothelioma phenotype did
not change either (Table 1). KRT7/CK7 and TYMP both gene
and protein was significantly overexpressed at resistance (Table 1,
Fig. 4). The protein encoded by the down-regulated gene
SPARCL1 was only slightly down-regulated after resistance.
Intrinsic resistance analysis
A simple quantification of gene expression in the long-term
survivor at diagnosis and the primary resistant and most aggressive
case with only six months survival (raw data from [8]) was
arranged by fold change (Fig. 5). Of 828 differentially over-
expressed genes, 188 (22.7%) were more than 2-fold overexpressed
in the resistant case and only 22 (2.6%) in the sensitive case.
Among those, the DNA repair genes and the genes with the
highest fold value are discussed. The findings are presented in the
respective section.
NT5C silencing in cell lines
The NT5C expression was silenced to 3467% of the original
expression level in the M-14-K cells and to 23614% in the ZL-34
cells, respectively. When comparing the mean values of controls
cells (for both M-14-K and ZL-34) with siRNA specific for NT5C
or negative control siRNA, no significant differences were found
when looking on the total amount of cells and on the cell cycle
distribution. No significant differences were seen when comparing
the pemetrexed treated cells, with silenced NT5C or with negative
control siRNA (Figure S3). However, we could see some minor
differences between the two groups of Pemetrexed treated ZL-34
cells. After treatment, there was 5 percentage points more live cells
in the ZL-34 that had been silenced than in the control cells. The
cell cycle distribution was also slightly changed in the silenced cells
having 6 percentage points more cells in G1 phase, 9 percentage
points less cells in S phase and 5 percentage points more cells in
the G2 phase.
Serum Biomarkers
Serum Mesothelin Related Protein (SMRP) was measured at
several time-points, as well as CA125 and CYFRA 21-1. CYFRA
21-1 was below the cut-off at diagnosis, and the value increased 2-
fold above cut-off only at resistance (not shown). SMRP was
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31.33 nM initially, 12-fold the normal value (2.5 nM), decreased
to 16.7 nM and was relatively stable until progression after
treatment pause, and subsequently increased after resistance to
treatment (Fig. 6). CA125 followed a similar course, initially 108
kIE/L, 3-fold normal value of 35 kIE/L, stabilized on 35 kIE/L
and increased after treatment pause and thereafter at resistance.
Discussion
To our knowledge this is the first published case of malignant
mesothelioma with a comparison of genome-wide expression at
the time of diagnosis and after pemetrexed-platinum therapy
failure. The shortcoming of this study is obviously the one case,
along with the caveats of microarray analysis of heterogeneous
tumour samples that shows the expression of a tumour/stroma
system rather than tumour cells only. Furthermore, the biological
material was scarce and thus only selected IHC was used for
validation. However, all steps were optimized, from the way the
biopsies were obtained (needle biopsy) and handled (rapid freeze
and storage), as well as optimal RNA extraction and verification of
a high tumour content in all the samples in adjacent biopsy. To
improve validity the gene expression of profile after resistance was
tested against six mesothelioma and seven normal samples as well
as showing overlapping results in two different microarray
platforms. Here several important genes and pathways that may
reflect tumour response and subsequent resistance were detected.
In the following sections results that may have relevance in
pemetrexed- and platinum-resistance will be discussed and the
main findings are summarized in Fig. 7.
Metabolic process- DNA and RNA metabolism
The metabolic process entity included several overexpressed
genes involved in DNA and RNA metabolism. In pyrimidine
metabolism six genes (CAD, NT5C, POLA2, POLD1, RRM2B,
TYMP) and four in purine metabolism (NT5C, POLA2, POLD1,
RRM2B) were also overexpressed in the KEGG pathways.
Pemetrexed is a multifolate antagonist that inhibits replication
through folate-dependent enzymes, thymidylate synthase (TS),
GARFT and DHFR where the affinity for the TS is many orders
of magnitude higher than the latter two, and is recognised as the
main target of pemetrexed in cell line experiments [19]. TS
encoded by TYMS, is a key protein that catalyzes the methylation
of deoxyuridylate (dUMP) to deoxythymidylate (dTMP) that
maintains the dTMP pool critical for DNA replication and repair.
Figure 2. Pyrimidine metabolism in tumour versus normal and at acquired resistance. Genes involved in pathways of DNA metabolism
and production in tumour versus normal (red corresponds to overexpressed and dark green correspond to down-regulated) and in acquired resistant
tumour (in ovals, all were overexpressed). Abbreviations: 2.1.3.2 = aspartate transcarbamylase 3.5.2.3 = dihydroorotase 6.3.5.5 = CAD; carbamoyl-
phosphate synthetase 2 3.1.3.5 = NT5C; 59-nucleotidase 2.7.7.7 = POLA2; DNA polymerase alpha subunit B 2.7.7.7 = POLD1; DNA polymerase delta
subunit 1 1.17.4.1 = RRM2B; ribonucleoside-diphosphate reductase subunit M2 2.4.2.4 = TYMP; thymidine phosphorylase.
doi:10.1371/journal.pone.0040521.g002
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Low TS expression increases the pemetrexed response in vitro
[20,21]. In our previous study, we noted that this good responder
had a very low TYMS mRNA and TS protein expression seen by
IHC in contrast to all the other cases with a mean survival of only
12 months [8]. After resistance, TS staining increased from below
1% to 25% of the cells (Table 1, Fig 4) while TYMS mRNA did
not change. Interestingly, studies have also shown that the
thymidylate synthase protein, and not the gene, is the only marker
to predict pemetrexed resistance in mesothelioma, in line with our
findings [3,4,5].
Acquired pemetrexed resistance of cancer cells in vitro and in
a murine model in vivo has been shown with addition of thymidine
that blocks pemetrexed effect on TS, hypoxanthine that blocks
GARFT and the combination of thymidine and hypoxanthine that
blocks DHFR [20,21]. In a one-patient study thymidine was
successfully used to reverse kidney failure due to pemetrexed,
indicating that at least the toxic effects of pemetrexed can be
blocked in humans by thymidine [22]. We found overexpression of
NT5C, encoding pyrimidine 5-prime nucleotidase also called
uridine 5-prime monophosphate hydrolase (UMPH), essential for
the catalyzing the dephosphorylation of thymidylate (TMP) to
thymidine and inositol monophosphate (IMP) to inositol, the
precursor of hypoxanthine. Knockdown of NT5C in colorectal
cancer cell lines sensitized cells to 5-FU, a drug also targeting TS
[23]. Thus, as elevated levels of thymidine and hypoxanthine have
been shown to reverse the pemetrexed effect, an elevated NT5C
could thus also be a potential pemetrexed resistance mechanism in
vivo (Fig. 7). Because of this, we silenced NT5C in two
mesothelioma cell lines, one sarcomatous and one of epithelial
type, that were treated with pemetrexed. There was no
sensitization of the silenced cells to pemetrexed, only a slight
change in cell cycle distribution was seen with in the G1 and G2
phase (Figure S3). Thus, a key role of this gene in pemetrexed
resistance could not be determined in vitro for these cell lines.
Contributing factors could be that the halftime and activity of
NT5C is not known and the actual amount of the protein in the
silenced cells is also unknown and this might affect the outcome of
these experiments.
Thymidylate phosphorylase mRNA (TYMP) as well as its
encoded protein (ECGF1 antibody) was overexpressed at re-
sistance (Fig. 4). TYMP is expressed at higher levels in a wide
variety of solid tumours than in adjacent non-neoplastic tissue and
been related to tumour progression and aggressiveness. Tumour
microenvironment (hypoxia, acidosis) regulates the expression of
TYMP, and its expression in tumour tissue shows significant
correlation with microvessel density and poor prognosis [24].
TYMP facilitates the conversion of thymidine to thymine and 2-
Deoxy-D-ribose, that has been shown as a key control of
Table 2. Top 10 overexpressed and down-regulated pathways in post- versus pre-resistance tumour in KEGG pathways map.
Overexpressed genes in KEGG pathways after resistance
Pathway code and name Number of genes
hsa01100 Metabolic pathways 18
hsa00240 Pyrimidine metabolism 6
hsa04144 Endocytosis 5
hsa00970 Aminoacyl -tRNA biosynthesis 4
hsa00230 Purine metabolism 4
hsa04020 Calcium signaling pathway 4
hsa04120 Ubiquitin mediated proteolysis 3
hsa05010 Alzheimer’s disease 3
hsa04141 Protein processing in endoplasmic reticulum 3
hsa05100 Bacterial invasion of epithelial cells 3
Down-regulated genes in KEGG pathways after resistance
Pathway code and name Number of genes
hsa01100 Metabolic pathways 11
hsa04514 Cell adhesion molecules (CAMs) 9
hsa04670 Leukocyte transendothelial migration 9
hsa04530 Tight junction 8
hsa04510 Focal adhesion 6
hsa05200 Pathways in cancer 6
hsa04010 MAPK signaling pathway 6
hsa04060 Cytokine-cytokine receptor interaction 5
hsa00230 Purine metabolism 5
hsa04520 Adherens junction 5
Several interesting and important systems were deregulated after resistance. Note that overexpressed genes in GO metabolic process was 89 and in KEGG only 18. The
reason is that KEGG includes new genes in a pathway only when several publications have confirmed it, and thus is more conservative but with a high level of evidence.
Most pronounced were the metabolism and modification of DNA and RNA through pyrimidine and purine metabolism and aminoacyl-t-RNA biosynthesis. Interestingly,
down-regulation of cell adhesion molecules and leukocyte transendothelial migration as well as cytokine-cytokine receptor interaction was pronounced, also an
expression characteristic of mesothelioma versus normal pleura.
doi:10.1371/journal.pone.0040521.t002
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angiogenesis and tumour progression (Fig. 2) [25]. TYMP is also
involved in fluorouracil metabolism and indispensable for the
action of capecitabine. Here, we found a low gene and protein
expression in the primary setting and highly expressed gene and
protein in the post-resistance sample, indicating a role in
progression, possibly also in resistance. RRM2B is a ribonucleotide
reductase that contributes to DNA repair by supplying deoxynu-
cleotide triphosphate pools in response to DNA damage, and has
been associated to treatment sensitivity and tumour invasiveness.
Silencing of this gene in prostate cancer sensitizes the tumour cells
to both irradiation and doxorubicin [26] as well as reversal of
acquired resistance to gemcitabine, which also showed cross-
resistance to pemetrexed in cell lines with acquired resistance
[27,28]. RRM2B role in mesothelioma is unknown, but a role in
pemetrexed resistance is highly plausible regarding its role
upstream of TS and a central role in DNA metabolism (Fig. 2).
CAD, encoding a multifunctional protein that initiates and
regulates mammalian de novo pyrimidine biosynthesis and is
required for mammalian cells to proliferate, was found highly
overexpressed. In k-FGF transfected cancer cells that developed
resistance to methotrexate, CAD and DHFR were the main genes
responsible for the resistance [29]. Furthermore, four genes
Figure 3. Genes changed more than 2-fold after resistance. Expression of genes that changed more then 2-fold in the post-resistance tumour,
compared to initial tumour. Down-regulated genes are shown to the left (30 in total, two not shown) and the overexpressed to the right (15, three
not shown). Green bars represent the relative gene expression before and red bars after acquired resistance.
doi:10.1371/journal.pone.0040521.g003
Figure 4. Tumour before resistance and at acquired resistance. Immunohistochemical images (x40) seen before treatment (top row) and five
years later after acquired resistance (bottom row). Three of the experimental markers that were hypothesised to be important for mesothelioma
aggressiveness as well as resistance, showed increased protein staining after acquired resistance. Chk1 staining increased from below 5% to 50% of
the cells, TYMS staining from below 1% to 25% of the cells while nuclear staining of NQO1 increased from 20 to 70% of the cells. Two novel putative
resistance markers, KRT7/CK7 and TYMP both gene and protein was significantly increased at resistance. SPARCL1 showed a significant decrease in
gene expression, but its encoded protein, hevin, showed only a slight decrease in protein staining intensity.
doi:10.1371/journal.pone.0040521.g004
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encoding proteins that load amino acids on t-RNA, MARS,
FARS2, WARS, AARS were in the top GO overexpressed group
fold-wise, as well as in KEGG pathways. Interestingly, as we have
proposed previously, t-RNA aminoacylation could be involved in
treatment resistance to ranpirnase [8,30].
TIMELESS, a circadian rhythm gene involved in DNA damage
response and replication was overexpressed in both our studies.
Elevated mRNA levels in breast cancer of this positive circadian
regulator has been significantly associated with shorter relapse-free
survival and recently been regarded as a promising marker of
tamoxifen resistance in women with estrogen receptor alpha-
positive breast tumours [31].
TNKSBP1, Tankyrase-1 was overexpressed and was previously
found to polymerize of poly(ADP-ribose) and to be required for
spindle structure and function [32]. TNKSBP1 mRNA in urine
sediment from patients with bladder carcinoma correlated with
tumour stage, and higher preoperative levels were associated with
increased risk of early recurrence [33]. The poly (ADP-ribose)
polymerization genes PARP9, 10 and 14 were overexpressed.
Generally little is known about their function, but PARP9 and 14
are also called B aggressive lymphoma proteins (BAL-family) and
mediates protection against apoptosis at DNA damage [34].
RBBP7, retinoblastoma protein 7, also overexpressed, is one
among several proteins that binds directly to the retinoblastoma
protein, which regulates cell proliferation. Both mRNA and
protein levels were found significantly overexpressed in non-small
cell lung cancer tissues and elevated serum levels were highly
correlated with distant metastasis [35]. It also plays an important
role in epithelial-mesenchymal transition [36]. In general, those
genes may play a role in pemetrexed resistance, but less likely in
resistance against platinum compounds.
DNA repair gene overexpression
DNA is the main cytotoxic target of cisplatin and carboplatin by
the induction of single and double-strand DNA breaks through
adducts and cross-linking, leading to cell death through apoptosis
[7]. To counteract the DNA damage induced by a platinum
compound, a highly complex repair cascade of several mechan-
isms is recquired. Recently, the Fanconi anemia/BRCA2 (FA)
pathway and Homologous Recombination (HR), a DNA double
Figure 5. Fold-change of gene expression between a primary resistant mesothelioma with only six months survival and the primary
sensitive case with almost six years survival. The top figure shows the DNA repair genes found in [7], depicting a grave overexpression of these
genes in the primary resistant case. Among them, CHEK1, FANCD2 and TYMS also seem to be important for acquired resistance (in ovals). Among the
32 top overexpressed genes (arbitrarily .6-fold), the 23 are involved in cell cycle, cytokinesis, and spindle formation, and several are known to be
negative prognostic factors in other cancers. The marked differences in indicate which gene functions may be important for aggressiveness and
intrinsic treatment resistance in mesothelioma. KRT7 and SDC1 genes that changed significally at acquired resistance were also .2-fold
overexpressed in the aggressive case. NQO1, a putative treatment target where protein expression was increased in acquired resistance, was .2-fold
overexpressed in the aggressive case.
doi:10.1371/journal.pone.0040521.g005
Molecular Resistance Profile in Mesothelioma
PLoS ONE | www.plosone.org 9 August 2012 | Volume 7 | Issue 8 | e40521
Figure 6. Serum biomarker changes over time. Ca125 and Mesothelin (SMRP) biomarkers in serum were elevated at diagnosis and decreased
and increased according to the clinical and radiological regression and progression respectively. The straight horizontal dashed lines depict the
maximum normal values of the two markers. CYFRA 21-1 is not shown.
doi:10.1371/journal.pone.0040521.g006
Figure 7. Cartoon summarizing the most important findings related to pemetrexed-platinum resistance and tumour
aggressiveness in post- versus pre-treatment biopsies. All genes labelled red are significantly overexpressed except TYMS and CHEK1
where only the encoded protein overexpression was seen. Thymidylate synthase protein overexpression is a known resistance factor against
pemetrexed and the TYMP gene/protein was overexpressed. Pemetrexed inhibits the folate enzymes TYMS, GARFT and DHFR. Overproduction of
thymidylate and hypoxanthine can reduce the pemetrexed effect on all three enzymes and rescue tumour cells from pemetrexed toxicity. NT5C was
overexpressed and encodes an enzyme, 59, 39-nucleotidase, a key enzyme for production of thymidylate and hypoxanthine. TYMS and the
downstream metabolite 2-deoxy-D-ribose increase angiogenesis and tumour aggressiveness. POLA2 and POLD1 are important for DNA elongation,
telomerase extension and cell survival, but also for repair, namely nucleotide excision repair (NER, POLD1 combined with LIG3) and base excision
repair (BER, LIG3 with XRCC1) thus important for platinum resistance. Two novel DNA repair genes with undefined mechanism related to both drug
and radiation resistance, RECQL5 PRPF19, were overexpressed. Damage response gene CHEK2 and Chk1 protein was overexpressed, both involved in
delaying mitosis and facilitating DNA repair. Abbrevations: CHEK1/Chk1; checkpoint 1 kinase CHEK2; checkpoint 2 kinase dTDP; deoxythymidine di-
phosphate dTTP; deoxythymidine tri-phosphate dUMP; deoxyuridylate IMP; inositol mono-phosphate LIG3; Ligase III NT5C; 59, 39-nucleotidase,
cytosolic POLA2; DNA polymerase alpha subunit B POLD1; DNA polymerase delta subunit 1 TYMP; thymidine phosphorylase TYMS; thymidylate
synthase.
doi:10.1371/journal.pone.0040521.g007
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strand break (DSB) repair mechanism of perfect repair, has been
attributed the role as a coordinator of this cascade [37]. In our
previous study, several genes involved in HR were overexpressed
[8]. Of those genes, only the FANCD2 was overexpressed here.
FANCD2 is a key protein in this pathway as it interacts with
BRCA2 and further with the members of the FANC and RAD
family [37], and could thus play a role in platinum resistance in
our case. POLD1 encodes DNA polymerase delta that plays
a central role in chromosomal DNA replication, repair, and
recombination [38]. It was recently shown to be very important for
Nucleotide Excision Repair (NER) [39], known to be important
for cisplatin-induced damage (Fig. 7). LIG3 encode DNA ligase III
that is a key protein in Base Excision Repair (BER) together with
XRCC1, but was also recently involved in NER with POLD1, but
also with XRCC1 [40,41,42]. LIG3 overexpression was found to
predict progression of non-muscle invasive bladder cancer in
a large microarray study [43]. Homozygous mutation of LIG3
confers a high risk for pancreatic and other forms of cancer [44].
Some interesting novel DNA repair genes appeared over-
expressed in the tumour after resistance. PRPF19 encodes the
hPso4 protein that was induced 15- to 30-fold in cells by gamma
radiation and chemical mutagens. Loss of hPso4 expression
induced by siRNA results in accumulation of double strand breaks,
apoptosis, and decreased cell survival after DNA damage and
plays a major but previously undefined role in mammalian DNA
DSB repair [45]. RECQL5 encodes a helicase, Recql5 that plays
an important role in maintaining active DNA replication. It
prevents the collapse of replication forks and accumulation of DSB
and subsequent cell death after topoisomerase I poisoning by
irinotecan, probably acting as a regulator of HR and was recently
proposed as a treatment target [46]. Interestingly, Recql5 protein
is not widely expressed in normal or non-mesothelioma tumour
tissues (www.proteinatlas.org), and may thus be important both for
mesothelioma biology and resistance against DNA damaging
agents.
Damage response proteins delay the entrance of the damaged
cell into mitosis thus facilitating DNA repair. Here the CHEK2
gene was overexpressed (not enough tissue to examine protein
expression), and the Chk1 (checkpoint kinase 1) protein, encoded
by the CHEK1 gene increased its staining from below 5% to 50%
of the tumour cells after resistance (Fig. 4). Chk1 is a putative
treatment target, as selectively localized in tumour cells, and is
a key protein controlling the G2/M checkpoint and DNA repair as
well as playing a role in radiation- and chemo-resistance [47].
Recently, high-throughput RNAi screen identified CHEK1 as
target for sensitizing ovarian cancer cells to cisplatin and
pancreatic cancer cells to gemcitabine [48,49] as well as
mesothelioma cells to doxorubicin [50]. In our previous study,
comparing this case with the most aggressive, the last had an 8-fold
higher CHEK1mRNA expression (Fig. 5). Another indication on
the relation between CHK1 and pemetrexed is the finding that
caffeine, a CHK1 inhibitor sensitizes mesothelioma cell-lines for
pemetrexed, and thus may be a putative co-drug target for
mesothelioma [51]. CHEK1 appears as a very important gene in
resistance towards several DNA-damaging agents, and could be
a promising marker for pemetrexed-platinum response and
survival in mesothelioma.
Cell adhesion molecules and leukocyte transendothelial
migration
Cell adhesion molecules and leukocyte transendothelial migra-
tion were among the top down-regulated pathways (Table 2,
Fig. 8). Currently both pathways were found to correlate with
recurrence after operation of stage I lung cancer in four large
datasets, and thus seem to play a role in tumour aggressiveness
[52]. Their role in chemoresistance is not clear but we already
detected down-regulation of these pathways in mesothelioma
versus normal parietal pleura. Here, CDH5 or vascular endothe-
lial cadherin is a key protein controlling the endothelial barrier
and its disruption by specific antibody both amplifies metastasis in
normal mice and overcomes the genetic resistance in mice [53].
Moreover, CDH5 is a candidate tumour suppressor and low
expression strongly correlated to worse survival in neuroblastomas
[54]. Claudins are integral membrane proteins and components of
tight junctions that serve as a physical barrier to prevent solutes
and water from passing through between epithelial or endothelial
cell sheets. CLDN1 (Fig. 3) and CLDN5 are down-regulated in
many cancers [55] and also in mesotheliomas [56] and low
expression of these claudins are associated with more aggressive
prostate cancer [57]. Importantly, another tight junction gene,
OCLN, occludin, was shown to be closely involved in resistance to
apoptogenes as cisplatin and gamma irradiation, and re-expression
of OCLN sensitized cancer cells to these agents [58]. VCL,
vinculin encodes a cytoplasmic actin-binding protein regulating
cell shape, integrin clustering, force generation, and strength of
adhesion as well as regulating apoptosis. In colorectal cancer
versus normal mucosa it was down-regulated and correlated to
carcinogenesis, invasion, and metastasis of colorectal carcinoma
[59]. Interestingly, the activation of vinculin sensitized melanoma
to chemotherapy and increased adhesion of cells to extracellular
matrix ligands, numbers of cell-matrix adhesions, and downstream
signaling [60]. ESAM is specifically expressed at endothelial tight
junctions and on platelets, and its down-regulation decreases
neutrophil extravasation [61]. JAM2/JAMB inhibition decreases
leukocyte infiltration [62].
Low CXCL12 and VCAM1 has been related to both cancer
progression and improved prognosis in various cancers, but no
clear relation to chemo-resistance has been reported. The down-
regulation of leukocyte transendothelial micration and adhesion is
thus connected to several mechanisms related to tumour
aggressiveness and treatment resistance, although these have not
been connected to either pemetrexed nor mesothelioma pre-
viously.
Candidate resistance markers
In the gene expression profile of malignant mesothelioma versus
normal pleura recently published, we found signatures related to
multi-resistance [8]. If we recognize this signature as mesotheli-
oma-specific, then the genes that are shared with the signature of
acquired resistance should be of high importance. There were 150
genes common between the top 1500 tumour versus normal gene
list and resistance profile (Supplemetary Excel Sheet 8) among
them KRT7 was highly overexpressed (Fig. 3), and the most
striking change in immunoreactivity was observed in its encoded
protein cytokeratin 7 (CK7) with a 75% augmentation of the
number of cells stained (Table 1, Fig. 4). Positivity for CK7 in
more then 75% of cells is regularly observed in several types of
carcinoma (www.proteinatlas.org), as well as mesotheliomas [63],
but to our knowledge there has not been reported such a degree of
augmentation of immunoreactivity for cytokeratins in the course of
therapy resistance in carcinomas, nor in mesothelioma. Evidence
for KRT7 in resistance specifically against anti-metabolites was
shown by cellular response to 5-fluorouracil in 5-FU-resistant
colon cancer cell lines during treatment and recovery where
KRT7 was among the differentially overexpressed genes [64].
Moreover, when pre-treatment expression was compared with the
expression in a primary resistant case, KRT7 was 3.2-fold
overexpressed in the aggressive case (Fig. 5). Thus, this gene-
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protein couple could be explored further as a marker of tumour
aggressiveness as well as for pemetrexed/carboplatin resistance.
SDC1 and its encoded protein syndecan-1 (CD138) are over-
expressed in mesothelioma and myeloma, but downregulation
rather than overexpression has been linked to drug resistance [65].
Intriguingly, while SDC1 mRNA was overexpressed, the IHC
showed down-regulation, thus pointing at a post-translatory
degradation process involved (data not shown). Thus, only
SDC1 mRNA expression could be further studied as a putative
resistance marker.
Among the down-regulated, both transcripts of SPARCL1,
encoding hevin, were changed more than 2-fold (Fig. 3). This gene
has recently been assigned a tumour suppressor role as well as
down-regulation in metastasis in pancreatic cancer [66]. Hevin
IHC was chosen due to its primarily high gene expression and
high down-regulation at resistance. It showed very strong staining
in all pre-treatment tumour cells but only a slightly less strong
staining post-resistance. Thus, SPARCL1 mRNA only could be
a putative resistance marker. Of the remaining genes there is no
established relation to pemetrexed or platinum resistance, but
PMP22, SRPX are indicators of increased tumour progression
and/or aggressivity in other cancers [67]. OSR1 is a transcription
factor that regulates p53 in concert with other genes, and its
overexpression activates p53 [68]. This may be very important but
a direct role the progression of cancer has not been described.
CDKN1B or its encoded protein p27 down-regulation is involved
in several cancers, in mesothelioma low p27 protein expression
correlated with short survival [69]. Low p27 also was predictive to
survival of breast cancer after fluorouracil, cyclophosphamide, and
methotrexate treatment [70]. Interestingly CDKN1B was down-
regulated both in tumour versus normal and after resistance
(Fig. 8). Recently, low p27 expression in lung cancer cells was
correlated to pemetrexed resistance [71]. With this background,
CDKN1B could also be explored as a putative resistance marker
in mesothelioma. Selenoprotein 1 (SEPP1) was down-regulated as
found in small-cell lung cancer [72].
Protein versus mRNA expression
The following genes were all overexpressed in our previous
study of mesotheliomas versus normal pleura, and were proposed
as targets for treatment. We wanted to assess whether the protein
expression of those genes was related to pemetrexed/carboplatin
resistance.
TS and CHEK1 were discussed in the previous section. NQO1
is a detoxifying reductase, where lack of function in somatic cells is
related to increased benzene oncogenesis and inactivating poly-
Figure 8. Leukocyte transendothelial migration in tumour versus normal parietal pleura and at acquired resistance. Leukocyte
transendothelial migration were among the top down-regulated pathways. Here we show the tumour versus normal profile with overexpressed (red)
and down-regulated (green) genes, and genes marked with oval were down-regulated post-resistance. Abbrevations: CDH5; cadherin 5, type 2
(vascular endothelium) CLDN1; claudin 1 CLDN5; claudin 5 CXCL12; chemokine (C-X-C motif) ligand 12 ESAM; endothelial cell adhesion molecule
JAM2; junctional adhesion molecule 2 OCLN; occludin (EC:2.1.1.67) VCAM1; vascular cell adhesion molecule 1 VCL; vinculin.
doi:10.1371/journal.pone.0040521.g008
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morphism has been related to dismal prognosis and predictive of
treatment failure in breast cancer [73]. In tumour cell over-
expression this is common and shown to induce proliferation in
melanoma cells [74]. The encoded protein NQO1 was primarily
highly expressed in cytoplasma, but low expressed in the nucleus.
Although the gene was not differentially expressed at resistance,
nuclear protein expression increased from 20 to 70%. Again, in
our previous study, the NQO1 mRNA in the most aggressive and
primary resistant case was 5.5-fold overexpressed (Fig. 5). Thus
nuclear expression of this protein may as well be a marker of
resistance. Previously we proposed this protein as a treatment
target, as its overexpression is a prerequisite for the effect of the
novel anticancer compound beta-Lapachone [75] that induce
selective tumour apoptosis by an unknown mechanism, as well as
radio-sensitisation in vitro. Moreover in cell lines beta-Lapachone is
found to inhibit DNA polymerase alpha, DNA replication and TS
activity, topoisomerase I, NFkappa-beta activity as well as
induction of topoisomerase II alpha mediated DNA breaks [76].
Most of these pathways were overexpressed in mesothelioma, and
thus this compound could be an interesting combination possibly
with pemetrexed and platinum.
RAD21 gene expression was not differentially expressed and
RAD21 protein expression was high in the primary biopsy where
90% of cells were positive, but there was a slight increase both in
intensity and positive cell count after resistance. RAD21 is a critical
gene in double-strand DNA repair and mitotic growth and gene
overexpression was recently shown to be involved in invasion and
metastasis in oral squamous cell carcinoma [77]. Silencing of
RAD21 gene expression decreased cell growth and enhanced
cytotoxicity of etoposide and bleomycin in human breast cancer
cells [78].
AGGF1, a recently discovered potent angiogenic [79], and is
implicated in damage response related to radiation defence, as
ionizing radiation induces overexpression of AGGF1 in lympho-
blastoid cells [80]. VG5Q, the protein encoded by this gene was
highly overexpressed in more then 95% of tumour cells, and after
progression virtually 100%. As it did not change significantly this
gene/protein may not be directly involved in pemetrexed and
platinum resistance but could be important for progression
through stimulating neo-angiogenesis.
Finally, with the exception of membrane EMA, the routine
immunohistochemical markers were not altered after resistance,
and thus cannot serve as resistance markers or markers of
changing biology (Table 1).
Gene expression of the most sensitive versus the most
aggressive case
In order to explore the possible gene expression differences of
a sensitive case with more resistant case, the fold change of
expression was compared with a case in our previous study with
only six months survival [8]. The analysis revealed highly
overexpressed DNA repair genes in the aggressive case (Fig. 5).
Many-fold difference was detected in CHEK1, TOP2A and genes
related to double-strand break repair. The TYMS gene was
overexpressed only 1.5-fold. The aggressive case also had 8.25-fold
increased HJURP and 11-fold increased CENPA. Recently, these
genes were found to be involved in DNA double strand break
repair and cell segregation as well as survival in breast cancer [81].
Interestingly, only CCNO/UNG2 was underexpressed in the
aggressive tumour, and there is a hypothesis how this may
contribute to antifolate resistance [82]. The glycosylase UNG2
initiates and is the rate-limiting factor for Base Excision Repair
(BER) of uracil [83]. In nature, toxic uracil incorporation in DNA
is removed by UNG2 and replaced by dTTP as should be. When
dTTP is lacking due to antifolate treatment, the DNA break persist
and the cell enters apoptosis. Overexpressed UNG2 and
concordant BER could thus confer to more DNA breaks and
tumour cell kill, while a low expression would not induce the same
amount of DNA breaks and thus inhibit the effect of pemetrexed.
Among the top overexpressed genes in the primary resistant
case versus the sensitive case, several very interesting genes were
found (Fig. 5, fold-change within brackets in the text). The gene
with the highest difference between aggressive and responsive
tumour was the KRT14 (Keratin 14) (93-fold) where it recently
was shown that the presence of Keratin14 positive progenitor
airway epithelial cells in NSCLC predicted a poor prognosis, and
this predictive value was strongest in smokers, in which it also
correlated with metastasis [84]. OXTR, oxytocine receptor gene
(80-fold) has also been detected in breast cancer cells with intrinsic
and acquired resistance to doxorubicin [85]. Radio-resistance,
early recurrence and metastasis are related to high CCNB1 (17.4-
fold) expression in head and neck cancer as well as acquired radio-
resistance, possibly through the activation of NFkB and other anti-
apoptotic mechanisms [86,87]. The KIF14 (Kinesin 14) (13-fold) is
an oncogene related to several cancers and where mRNA
overexpression is a negative prognostic factor in lung and breast
cancer [88]. CEP55 (12-fold) encodes a centrosome-related gene
where high expression was negative prognostic for head and neck
cancer and its down-regulation inhibited migration and metastasis
of cells [89]. SERPINB5 (9.8-fold) is strongly associated to breast
cancer metastasis [90] and negative prognostic in pancreatic
cancer [91]. BUB1 (9.6-fold) and BUB1B (5.7-fold) are involved in
the spindle assembly checkpoint, and overexpression of BUB1B
significantly correlated with higher histological grade, advanced
pathological stage, and high cell proliferation in bladder cancer
and predicted tumour recurrence and disease progression [92].
BUB1 is also a possible negative prognostic factor in mesothelioma
[93]. Survivin, encoded by BIRC5 (7.6-fold) has, besides its anti-
apoptotic function, a role in microtubule dynamics and control
bipolar spindle formation [94]. Survivin is overexpressed in many
human cancers, associated with resistance to chemotherapy or
radiation therapy, and linked to poor prognosis, also in
mesothelioma [95,96]. Importantly, survivin also seems to control
Ran, encoded by RAN (2-fold). Ran is a small GTPase regulator
of mitotic spindle formation and is overexpressed in human cancer
as compared with normal tissues. Gene silencing of RAN induces
aberrant mitotic spindle formation, mitochondrial dysfunction,
and apoptosis [97]. CDC2 (9.4-fold) is a spindle checkpoint gene
and overexpression is a negative prognostic factor in several
tumours [98] as well as a putative treatment target in gliomas [99].
Its overexpression was also verified in a cohort of 84 mesotheli-
omas [50]. LRP8 (8-fold) is overexpressed in lung cancer and
involved in lung tumorigenesis [100]. CDC20 (7.5-fold) appears to
act as a regulatory protein in the cell cycle and is required for two
microtubule-dependent processes, nuclear movement prior to
anaphase and chromosome separation. A signature of genes
including CDC20, CCNB1, CDC2, CDKN3, MAD2L1, PRC1
and RRM2, were prognostic for 5-year survival in over 400 lung
cancer cases [101], and interestingly, CDC20, CDC2, CCNB1
were also highly overexpressed in the aggressive case. E2F7 (7.4-
fold) is implicated in damage response to DNA damaging agents
[102]. CCNB2 (7.4-fold) another cyclin overexpressed in several
cancers, was interestingly proposed as a serum marker for various
cancers as serum CCNB2 mRNA was significantly elevated in
patients versus benign diseases or normal [103]. AURKA (6.8-
fold) overexpression leads to centrosome amplification, genetic
instability and transformation, as well as cisplatin resistance. Its
activation of the NFkB pathway has been proposed as an
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important mechanism [104]. AURKA is overexpressed in several
cancers, and has been associated with shorter survival in
mesotheliomas [105] and small molecule inhibitors of AURKA
are currently in phase II trials [106]. MKI67 (6.2-fold) encodes an
antigen identified by monoclonal antibody Ki-67, a nuclear
protein and proliferation marker that is a negative prognostic for
pleural mesothelima [69].
Among those top overexpressed genes, 23 are involved in cell
cycle (Fig. 9), cytokinesis, and spindle formation, and several are
known to be negative prognostic factors in other cancers. The
grave difference in gene expression between these two phenotyp-
ically different cases in the primary situation indicate that some
important systems are more deregulated in the aggressive case.
However, most of the genes that changed in acquired resistance
were different.
Serum biomarkers
Neither the MSLN gene nor its encoded protein changed in
tumour at resistance and tumour growth (Table 1) but serum
mesothelin was reduced at response and increased at resistance
(Fig. 6). While serum mesothelin is a valuble mesothelioma marker
for diagnosis and disease progression, we have previously shown
that increased mesothelin expression in tumour was not associated
to shorter survival, rather the opposite [15], lending notion to the
theory of tumour burden as the main source of SMRP change and
not tumour aggressiveness. Similarly, serum CA125 was positively
associated to clinical and radiological course, but its encoding gene
MUC16 did not change in the tumour, also indicating that tumour
burden and not differential gene expression in tumour increases
serum levels. Neither CYFRA21-1 in serum nor its encoding
KRT19 gene in the tumour changed significantly.
Conclusion
More than half of mesothelioma patients do not respond to the
standard treatment of pemetrexed and cisplatin and acquired
resistance in responders is almost obligate. Thus, biological
information leading to tailored treatment is clearly warranted.
We present here for the first time, an example of in vivo
resistance gene profile of pemetrexed-carboplatin treatment in
mesothelioma. At resistance the TS protein, the main target of
pemetrexed increased. DNA damage response, repair, elongation
and telomere extension, related directly and indirectly to platinum
resistance were overexpressed, such as the CHEK2 gene, the
CHK1 protein, the POLD1, POLA2, LIG3, FANCD2 and finally
Figure 9. Cell cycle changes tumour versus normal and acquired resistance. Cell cycle was one of the KEGG pathways with most de-
regulated genes both in tumour versus normal (23 genes- red correspond to overexpressed, dark green correspond to down-regulated) involved in
all phases of the cell cycle (G1-S-G2-M). At acquired resistance, only CDKN1B (in oval) was down-regulated and CHEK2 was overexpressed (in oval).
Abbrevations: CDKN1B; cyclin-dependent kinase inhibitor 1B (p27, Kip1) CHEK2; checkpoint kinase 2.
doi:10.1371/journal.pone.0040521.g009
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the novel DNA repair genes PRPF19 and RECQ5, not previously
described in mesothelioma. Down-regulation of leukocyte trans-
endothelial migration and cell adhesion genes were overrepre-
sented and are novel pathways involved in resistance and tumour
aggressiveness. Overexpression of KRT7 along with its encoded
protein CK7 and TYMP with its encoded highly pro-angiogenic
thymidine phosphorylase protein as well as down-regulated
SPARCL1 and CDKN1B are proposed resistance markers.
Comparison of the primary expression of the sensitive versus
a primary resistant case showed multi-fold overexpressed DNA
repair, cell cycle, cytokinesis, and spindle formation in the latter.
Serum CA125 and SMRP reflected the clinical and radiological
course and probably tumour burden.
The present analysis and previous microarray study is to our
knowledge the only genome-wide profiling study on mesothelioma
patients receiving chemotherapy as the main treatment, which is
by far the largest group of patients treated in clinical practice [9].
Thus, these findings should be confirmed in a larger patient cohort
with profiling of biopsies before treatment and after treatment
failure. Such a study is strongly recommended in order to achieve
a deeper understanding of mesothelioma resistance mechanisms in
vivo and identify the markers that may guide treatment decisions to
improve and personalize treatment in this patient group.
Supporting Information
Figure S1 Loading plots and Principal Component
Analysis (PCA). The coloured spots in the loading plots above
represent differentially expressed genes where red spots in the
middle represent Affymetrix and blue represent Illumina, green
represent low variance genes overlapping differentially expressed
genes between the platforms. The PCA score-plots of the gene
expression of the same RNA from the same samples on Affymetrix
and Illumina platforms below are virtually identical (see case IDs),
where red are tumour and black are parietal pleura samples.
(TIFF)
Figure S2 Venn diagram of up- (red) and down-regulat-
ed (green) genes of mesothelioma tumour versus normal
parietal pleura. An overlap between the Affymetrix and
Illumina platforms of 65% is seen.
(TIFF)
Figure S3 Silencing of NT5C and pemetrexed treat-
ment. Cell cycle distribution of NT5C silenced (+) or negative
siRNA control (–) in malignant mesothelioma cells, after 48 hours
of pemetrexed treatment. The percentages represent the amount
of live cells in control and pemetrexed treated cells. Levels of
significance: * = P,0.05, ** = P,0.01, *** = P,0.001, ****
= P,0.0001.
(TIFF)
Table S1 siRNA specific for NT5C (Sigma-Aldrich).
(DOCX)
Table S2 Sheet 1–8. Sheet 1–3. The top 1500 ranked list and
GO entities of differentially expressed genes showed an over-
expression of genes involved in mitosis, cell cycle checkpoint and
DNA repair and down-regulated multicellular organismal de-
velopment, inflammatory response and vasculogenesis among
others. Sheet 4–7. High quality RNA was successfully extracted
from the post-resistance tumour samples and analysed with the
Illumina platform as described. The acquired resistance analysis
revealed 241 overexpressed and 289 down-regulated genes in the
post-resistance samples (Sheet 4 and 5). There were 23
significantly overexpressed and 65 down-regulated GO-terms
(Sheet 6 and 7, p,0.05). Sheet 8. Acquired resistance and
tumour profile. Common gene list.
(XLS)
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